Navigation Links
OHSU Doernbecher Children's Hospital conducts second phase of landmark Batten study
Date:10/29/2010

PORTLAND, Ore. Oregon Health & Science University Doernbecher Children's Hospital will lead the next phase of a landmark clinical trial to further assess the safety and preliminary effectiveness of purified human neural stem cells (HuCNS-SC) as a potential treatment for infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare and currently fatal neurodegenerative disorder that affects infants and children.

The Phase Ib trial, sponsored by StemCells, Inc., is designed to further assess the safety and preliminary effectiveness of StemCells' HuCNS-SC as a potential treatment for NCL, also referred to as Batten disease. This second trial is expected to enroll six children whose NCL is less advanced than those enrolled in the initial Phase I trial, also carried out at OHSU Doernbecher, and, in addition to safety, is also designed to evaluate the impact of HuCNS-SC on disease progression.

"The hard work of testing neural stem cells for their safety and effectiveness in clinical use began here at OHSU Doernbecher Children's Hospital. We are very pleased to carry on this important effort with a second major trial. Our great hope is that this work will eventually yield significant benefits for patients who suffer from devastating nervous system diseases," said Nathan Selden, M.D., Ph.D., FACS, FAAP, Campagna Professor of Pediatric Neurosurgery and head of the Division of Pediatric Neurological Surgery at OHSU Doernbecher Children's Hospital, OHSU School of Medicine.

Selden was co-principal investigator on the groundbreaking initial Phase I trial and will lead the Ib study.

The initial trial was the first-ever FDA-authorized clinical trial of purified human neural stem cells as a potential therapeutic agent. Begun in March 2006, its aim was to test the safety and preliminary efficacy of transplanting HuCNS-SC in six children with advanced stages of NCL. Once transplanted, the children were followed for 12 months. Data from the Phase I trial, completed in January 2009, demonstrated that high doses of HuCNS-SC transplanted directly into multiple sites within the brain followed by 12 months of immunosuppression were well tolerated. The data also included evidence of engraftment and long-term survival of the donor cells.

Participants in the new study will be transplanted with HuCNS-SC via a neurosurgical procedure and their immune systems will be suppressed for nine months. Following transplantation, the children will be monitored and regularly evaluated for 12 months to assess the safety and tolerability of the HuCNS-SC, the surgery and the immunosuppression. In addition, participants will be evaluated and assessed at regular intervals using a comprehensive range of clinical and X-ray tests, both before transplantation to establish a baseline, and over the course of 12 months following transplantation.

StemCells, Inc. will initiate a separate four-year observational study at the conclusion of this trial.


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related biology news :

1. Childrens Hospital LA discovers growth factor essential to epicardial cell function
2. Malnutrition increases risk of prolonged hospital stay
3. McLean Hospital researchers awarded $1.9 9 million grant for stem cell, blood research
4. Vitamin C rapidly improves emotional state of acutely hospitalized patients, say LDI researchers
5. Opioid use to relieve pain and suffering at end of life is safe in hospital-at-home setting
6. Researchers at Childrens Hospital Los Angeles find diet-induced obesity accelerates leukemia
7. Memorial Hospital Selects DigitalPersona Pro to Enhance HIPAA Security
8. Texas Childrens Hospital vaccine experts present 4 studies
9. Nude-colored hospital gowns could help doctors better detect hard-to-see symptoms
10. Temple University Hospital and PASNAP Negotiations Break Off: Talks to Resume Later Today
11. Researchers find Clostridium difficile is more common than MRSA in southeast community hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... to the scientific and clinical research community’s growing body of knowledge during its ... in the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, ...
(Date:4/20/2017)... MN and Bethesda, MD (PRWEB) , ... April ... ... Advancing Innovation announce the formation of a unique intellectual property (IP) sharing and ... potential of their most promising inventions. A main component of this effort is ...
(Date:4/19/2017)... Yorba Linda, Ca (PRWEB) , ... April 18, 2017 , ... ... highlight new technological advances. This webinar, which is part of the Protein and ... NxT Flow Cytometer and outline where this technology fits in current and future applications. ...
(Date:4/19/2017)... (PRWEB) , ... April 19, 2017 , ... ... Clostridium difficile (C. diff) infections through education and advocacy. Founded in 2010 ... to a C. diff infection, the foundation has become the most-consulted source for ...
Breaking Biology Technology: